Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline Research & Development
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release (IR) Tablets or Ropinirole Prolonged Release / Extended Release (PR/XR) Tablets in Advanced Stage Parkinson’s Disease Subjects who are not Adequately Controlled on L-dopa
To demonstrate the superiority of ropinirole PR/XR tablets over ropinirole IR tablets when used as adjunctive therapy to L-dopa in subjects with advanced stage Parkinson’s disease who are not adequate...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 4 ans
Study to compare Umeclidinium when added to FP/SAL versus placebo when added to FP/SAL in COPD Patients. Hodnocení srovnávající Umeclidinium přidané k FP/SAL oproti placebu přidanému k FP/SAL u pacientů s CHOPN
The primary objective is to compare the efficacy and safety of the addition of UMEC (62.5mcg) once-daily to FSC (250/50mcg) twice-daily, UMEC (125mcg) once-daily to FSC (250/50mcg) twice-daily with pl...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 4 ans
A 6-month study to assess the safety and benefit of inhaled fluticasone propionate/salmeterol combination compared with inhaled fluticasone propionate in the treatment of adolescents (12 years and over) and adults with asthma
The primary objective of the study is to evaluate whether the addition of LABA to ICS therapy (FSC) is non-inferior to ICS therapy alone (FP) in terms of the risk of serious asthma related events (ast...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A randomised, double-blind, double-dummy, placebo-controlled, 3-way crossover study to evaluate potential next-day residual effects of a single evening dose of 3mg eszopiclone and 7.5mg zopiclone in healthy adult subjects
• To evaluate the existence and time course of potential next-day residual psychomotor effects of a single evening dose of 3mg eszopiclone, 7.5mg zopiclone, and placebo as measured by the mean trackin...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 4 ans
A randomised, double blind study to evaluate the safety and efficacy of the p38 kinase inhibitor, GW856553, in subjects with neuropathic pain from peripheral nerve injury
To investigate the effect of repeat oral dosing (28 days) of GW856553 on neuropathic pain in subjects with peripheral nerve injury.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 4 ans
A multi-centre, randomised, double-blind, parallel group study assessing the efficacy and safety of IV nesiritide versus placebo, in addition to background care, in the treatment of subjects with acute decompensated heart failure. Evaluating Treatment with Nesiritide in Acute Decompensated Heart Failure (ETNA)
The objectives of this study are to assess the efficacy and safety of IV nesiritide versus placebo, in addition to background care, in the treatment of subjects with adHF managed in an inpatient setti...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
Study to compare umeclidinium with tiotropium in COPD subjects
The primary objective of this study is to compare the efficacy and safety of UMEC 62.5 mcg with tiotropium 18 mcg in subjects with COPD over 12 weeks of treatment.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A study to investigate the effect of GW406381 on methotrexate pharmacokinetics in patients treated with methotrexate for rheumatoid arthritis
Evaluate the influence of repeated oral dosing of GW406381 on the plasma pharmacokinetics of methotrexate in rheumatoid arthritis patients.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 4 ans
A 14 week study where each subject takes 3 medicines (each for 2 weeks) being developed to treat COPD
The primary objective of this study is to evaluate the lung function response following treatment with UMEC 62.5mcg, VI 25mcg, and UMEC/VI 62.5/25mcg administered once-daily via the Novel Dry Powder I...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once- Daily in Subjects with Asthma
The primary objective of this study is to demonstrate that treatment with Fluticasone Furoate/GW642444 Inhalation Powder once-daily administered in the evening significantly decreased the risk of seve...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant